Amgen Announces Phase 3 Talimogene Laherparepvec Trial In Melanoma Met Primary Endpoint of Durable Response Rate

Amgen (NASDAQ: AMGN ) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). The study met its primary endpoint